Research Analysts Issue Forecasts for AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a report issued on Monday, February 10th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($1.48) per share for the quarter. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at $3.85 EPS and FY2028 earnings at $9.90 EPS.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Axsome Therapeutics in a report on Tuesday. Bank of America lifted their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a research note on Tuesday. Leerink Partners upped their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday. Truist Financial raised their price objective on Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, Mizuho upped their target price on Axsome Therapeutics from $137.00 to $195.00 and gave the stock an “outperform” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $147.13.

Axsome Therapeutics Trading Up 4.0 %

Axsome Therapeutics stock opened at $132.20 on Wednesday. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The firm has a market cap of $6.41 billion, a PE ratio of -20.25 and a beta of 1.05. The stock’s 50 day simple moving average is $95.28 and its two-hundred day simple moving average is $92.07. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $134.19.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. During the same period last year, the business earned ($1.32) earnings per share.

Institutional Trading of Axsome Therapeutics

Several large investors have recently bought and sold shares of the business. Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth $52,000. R Squared Ltd purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $64,000. KBC Group NV increased its holdings in shares of Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after buying an additional 385 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares during the last quarter. Finally, Moors & Cabot Inc. purchased a new position in Axsome Therapeutics in the third quarter worth approximately $200,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.